reltecimod (pending FDA approval)

Action and Spectrum

Actions and Spectrum: 

• reltecimod initiates the immune response of the host by adhering to the T-cell-expressed CD28 dimer interface.  
• The specific mechanism by which reltecimod modulates inflammation and its exact mode of action may require further investigation and clarification. However, the description suggests that reltecimod targets a critical pathway involved in the immune response to prevent excessive inflammation and subsequent organ dysfunction. 
• reltecimod’s activity is independent of the type of pathogen, implying that it may have a broad spectrum of activity and is not limited to specific bacterial strains or pathogens. 

Drug Interaction

Adverse Reaction

N/A 

Black Box Warning

Black box warning: 

N/A 

Contraindication / Caution

Contraindications/caution: 

Contraindications: 

N/A 

Caution: 

N/A 

Pregnancy / Lactation

Pregnancy consideration: N/A 

Lactation: N/A 

Pregnancy category: 

Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    

Category N: There is no data available for the drug under this category 

Pharmacology

Pharmacology: 

N/A 

Pharmacodynamics: 

N/A 

Pharmacokinetics: 

N/A 

Adminstartion

Administration: 

N/A 

Patient Information Leaflet

Patient information leaflet 

Generic Name: reltecimod (pending FDA approval) 

Why do we use reltecimod? 

reltecimod is being developed as an immunomodulator peptide to treat suspected organ dysfunction or failure in necrotizing soft tissue infection (NSTI) patients.